You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 10,350,213

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,350,213

Title:	Methods for treating cancer using apilimod
Abstract:	The present invention relates to methods for treating cancer with apilimod and related compositions and methods.
Inventor(s):	Lichenstein; Henri (Guilford, CT), Rothberg; Jonathan M. (Guilford, CT), Gayle; Sophia (East Haven, CT), Beeharry; Neil (Guilford, CT), Beckett; Paul (Yorktown Heights, NY), Landrette; Sean (Meriden, CT), Conrad; Chris (Guilford, CT), Xu; Tian (Guilford, CT)
Assignee:	AI Therapeutics, Inc. (Guilford, CT)
Application Number:	15/213,829
Patent Claims:	1. A pharmaceutical composition for treating cancer in a subject, the composition comprising apilimod, or a pharmaceutically acceptable salt thereof, and an inhibitor of a checkpoint signaling pathway involving a programmed death 1 (PD-1) receptor and/or its ligands (PD-L1/2). 2. The composition of claim 1, wherein the inhibitor is selected from BMS-936559/MDX-1105, MPDL3280A (atezolizumab), MSB0010718C (avelumab), MED14736 (durvalumab), CT-011/pidilizumab, BMS-936558/MDX-1106/nivolumab, and pembrolizumab, and combinations of two or more of any of the foregoing. 3. The composition of claim 1, wherein the composition further comprises one or more of ondansetron, granisetron, dolasetron, palonosetron, pindolol and risperidone. 4. The composition of claim 1, wherein the composition comprises apilimod dimesylate and MPDL3280A (atezolizumab).

Details for Patent 10,350,213

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	KEYTRUDA	pembrolizumab	For Injection	125514	09/04/2014	⤷ Try a Trial	2039-07-30
Merck Sharp & Dohme Corp.	KEYTRUDA	pembrolizumab	Injection	125514	01/15/2015	⤷ Try a Trial	2039-07-30
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	12/22/2014	⤷ Try a Trial	2039-07-30
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	10/04/2017	⤷ Try a Trial	2039-07-30
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	08/27/2021	⤷ Try a Trial	2039-07-30
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.